Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

• First mass spectrometry-based test system for total 25-Hydroxyvitamin D to receive CLIA 'Moderate Complexity' designation in the U.S.
• Expands access to advanced testing with a fully automated, standardized workflow on the cobas® i 601 analyzer
• Marks an important step in broadening the clinical utility of mass spectrometry testing across routine labs

INDIANAPOLIS, September 18, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has categorized its Ionify® 25-Hydroxy Vitamin D total assay as “Moderate Complexity" under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This represents the first time a mass spectrometry-based test has achieved this designation, opening access to a broader range of clinical laboratories.

The assay runs on Roche's cobas® i 601 analyzer, part of the cobas® Mass Spec solution. By combining mass spectrometry's sensitivity and specificity with a standardized, easy-to-use workflow, the cobas® Mass Spec solution streamlines complex testing and reduces variability across labs. Traditionally, these tests have been confined to highly specialized labs due to complex workflows and the need for expert operators.

“Achieving this level of automation for a mass spectrometry assay is a breakthrough for routine diagnostics," said Brad Moore, President and CEO, Roche Diagnostics North America. "It will allow more labs to deliver highly accurate results efficiently, helping clinicians make better-informed decisions and ultimately improving patient care.”

The Ionify 25-Hydroxy Vitamin D total assay is the first in Roche's planned U.S. pipeline for the cobas® Mass Spec solution. Roche already offers a broad menu of mass spectrometry assays in countries accepting the CE mark, with additional launches anticipated globally.

Roche's proprietary chemistry enables scalable automation with a workflow that is faster, more reproducible and more environmentally sustainable than conventional mass spectrometry methods. This reduces variability across labs and helps minimize the need for outsourcing advanced testing.

For more information, please visit go.roche.com/USMassSpec or visit Roche's booth at the upcoming Mass Spectrometry & Advances in the Clinical Lab (MSACL) Conference in Montreal, Canada, from September 21-26, 2025.